Document is current
Any future updates will be listed below
-
Authors
Battaglin, Francesca
Schirripa, Marta
Buggin, Federica
Pietrantonio, Filippo
Morano, Federica
Boscolo, Giorgia
Tonini, Giuseppe
Lutrino, Eufemia Stefania
Lucchetti, Jessica
Salvatore, Lisa
Passardi, Alessandro
Cremolini, Chiara
Arnoldi, Ermenegildo
Scartozzi, Mario
Pella, Nicoletta
Boni, Luca
Bergamo, Francesca
Zagonel, Vittorina
Loupakis, Fotios
Lonardi, Sara
-
Funding
Funding for this research was provided by:
Gruppo Oncologico Nord-Ovest (G.O.N.O.) Cooperative Group
-
More Information
Article History
Received: 14 September 2017
Accepted: 17 January 2018
First Online: 25 January 2018
Ethics approval and consent to participate
: The trial was approved by the Ethics Committee of the Istituto Oncologico Veneto IRCCS and by local Committees of participating centers. All study participants will provide their written informed consent after careful explanation by their treating investigators.
: Not applicable
: Fotios Loupakis is an advisor/speaker for Amgen Inc., Bayer Healthcare, Eli Lilly and Company and Roche. Sara Lonardi is an advisor/speaker for Amgen Inc., Bayer Healthcare, Eli Lilly and Company, Roche and Sanofi. Filippo Pietrantonio has advisory role/honoraria for Amgen Inc., Roche, Sanofi, Eli Lilly and Company and Bayer Healthcare. Mario Scartozzi is an advisor/speaker for Merck-Serono, Bristol-Myers Squibb, Amgen Inc., Bayer Healthcare, Eli Lilly and Company and Sanofi-Aventis.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
